ORIC Pharmaceuticals Inc.
ORICHeld by 8 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying8 funds opened new positions. Next phase2 readout (ORIC-114): Sep 2026. Short interest: 17.9% of float.
Held by 8 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying8 funds opened new positions. Next phase2 readout (ORIC-114): Sep 2026. Short interest: 17.9% of float.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.